924 related articles for article (PubMed ID: 11686357)
1. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD
Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
[TBL] [Abstract][Full Text] [Related]
2. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
[TBL] [Abstract][Full Text] [Related]
3. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
Cohen M
J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
[TBL] [Abstract][Full Text] [Related]
4. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).
Eur Heart J; 1999 Nov; 20(21):1553-62. PubMed ID: 10529323
[TBL] [Abstract][Full Text] [Related]
5. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
Montalescot G; Collet JP; Tanguy ML; Ankri A; Payot L; Dumaine R; Choussat R; Beygui F; Gallois V; Thomas D
Circulation; 2004 Jul; 110(4):392-8. PubMed ID: 15249498
[TBL] [Abstract][Full Text] [Related]
6. Effects of unfractionated and low molecular weight heparins on plasma levels of hemostatic factors in patients with acute coronary syndromes.
Vila V; Martínez-Sales V; Réganon E; Peris E; Perez F; Ruano M; Aznar J
Haematologica; 2001 Jul; 86(7):729-34. PubMed ID: 11454528
[TBL] [Abstract][Full Text] [Related]
7. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
N Engl J Med; 1997 Aug; 337(7):447-52. PubMed ID: 9250846
[TBL] [Abstract][Full Text] [Related]
8. Enoxaparin in acute coronary syndromes.
Lee S; Gibson CM
Expert Rev Cardiovasc Ther; 2007 May; 5(3):387-99. PubMed ID: 17489664
[TBL] [Abstract][Full Text] [Related]
9. The greatest benefit of enoxaparin over unfractionated heparin in acute coronary syndromes is achieved in patients presenting with ST-segment changes: the Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) Electrocardiogram Core Laboratory Substudy.
Goodman SG; Bozovich GE; Tan M; Dos Santos A; Gurfinkel EP; Cohen M; Langer A;
Am Heart J; 2006 Apr; 151(4):791-7. PubMed ID: 16569535
[TBL] [Abstract][Full Text] [Related]
10. Comparison of a low-molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogs.
Jun L; Arnout J; Vanhove P; Dol F; Lormeau JC; Herbert JM; Collen D; Van de Werf F
Coron Artery Dis; 1995 Mar; 6(3):257-63. PubMed ID: 7788040
[TBL] [Abstract][Full Text] [Related]
11. Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction.
Baird SH; Menown IB; Mcbride SJ; Trouton TG; Wilson C
Eur Heart J; 2002 Apr; 23(8):627-32. PubMed ID: 11969277
[TBL] [Abstract][Full Text] [Related]
12. Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin.
Santopinto J; Gurfinkel EP; Torres V; Marcos E; Bozovich GE; Mautner B; McCabe CH; Antman EM
Am Heart J; 2001 Apr; 141(4):566-72. PubMed ID: 11275921
[TBL] [Abstract][Full Text] [Related]
13. Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction.
Cheng S; Morrow DA; Sloan S; Antman EM; Sabatine MS
Circulation; 2009 Mar; 119(9):1195-202. PubMed ID: 19237657
[TBL] [Abstract][Full Text] [Related]
14. Clinical benefit of enoxaparin in patients with high-risk acute coronary syndromes without ST elevations in clinical practice.
Zeymer U; Gitt A; Jünger C; Koeth O; Zahn R; Wienbergen H; Gottwik M; Senges J;
Am J Cardiol; 2006 Jul; 98(1):19-22. PubMed ID: 16784913
[TBL] [Abstract][Full Text] [Related]
15. Comparison of anticoagulant and anti-inflammatory responses using enoxaparin versus unfractionated heparin for transesophageal echocardiography-guided cardioversion of atrial fibrillation.
Hoppensteadt D; Fareed J; Klein AL; Jasper SE; Apperson-Hansen C; Lieber EA; Katz WE; Malouf JF; Stoddard MF; Pape LA;
Am J Cardiol; 2008 Oct; 102(7):842-6. PubMed ID: 18805108
[TBL] [Abstract][Full Text] [Related]
16. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction.
Antman EM; Morrow DA; McCabe CH; Murphy SA; Ruda M; Sadowski Z; Budaj A; López-Sendón JL; Guneri S; Jiang F; White HD; Fox KA; Braunwald E;
N Engl J Med; 2006 Apr; 354(14):1477-88. PubMed ID: 16537665
[TBL] [Abstract][Full Text] [Related]
17. A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes.
Califf RM; Petersen JL; Hasselblad V; Mahaffey KW; Ferguson JJ
Am Heart J; 2005 Apr; 149(4 Suppl):S91-9. PubMed ID: 16124953
[TBL] [Abstract][Full Text] [Related]
18. The role of low-molecular-weight heparins in non-ST-segment elevation acute coronary syndromes.
Nguyen-Ho P; Levine GN
Panminerva Med; 2002 Jun; 44(2):115-22. PubMed ID: 12032429
[TBL] [Abstract][Full Text] [Related]
19. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials.
Mehta SR; Boden WE; Eikelboom JW; Flather M; Steg PG; Avezum A; Afzal R; Piegas LS; Faxon DP; Widimsky P; Budaj A; Chrolavicius S; Rupprecht HJ; Jolly S; Granger CB; Fox KA; Bassand JP; Yusuf S;
Circulation; 2008 Nov; 118(20):2038-46. PubMed ID: 18955665
[TBL] [Abstract][Full Text] [Related]
20. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin?
Henry TD; Satran D; Knox LL; Iacarella CL; Laxson DD; Antman EM
Am Heart J; 2001 Oct; 142(4):590-3. PubMed ID: 11579347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]